Radiothérapie et grossesse

Mazeron, R.; Barillot, I.; Mornex, F.; Giraud, P.

doi:10.1016/j.canrad.2016.07.024

Cited by 3 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Адъювантное лечение тамоксифеном противопоказано во время беременности из-за тератогенного эффекта, наблюдаемого в исследованиях на животных. В нескольких отчетах о случаях на людях были выявлены серьезные врожденные аномалии, такие как синдром Гольденхара или нарушение развития гениталий [36,37].…”

Section: опухоли женской репродуктивной системы Tumors Of Female Repr...unclassified

Combination of pregnancy and breast cancer

Chernyshova,

Chernyakov,

Garbukov

et al. 2023

Opuholi ženskoj reproduktivnoj sistemy

View full text Add to dashboard Cite

Breast cancer (BC) occupies the second place in terms of incidence and the first ranking place in terms of mortality among oncopathology in women. The article presents the current state of the problem of the combination of BC and pregnancy, the impact of pregnancy on the course and outcome of breast oncopathology, as well as modern hypotheses for the development of breast cancer during pregnancy. It is shown that the current studies are quite contradictory and in many ways not accurate enough in methodology and materials. We present a clinical case of BC associated with pregnancy. The case is interesting from 2 positions: on the one hand, the patient’s tumor process is associated with pregnancy, on the other hand, there is a very rare combination of HER2/neu- and BRCA1-positive status.According to the presented literature data and our own data, it was concluded that the treatment of patients with BC during pregnancy is a difficult task and is often accompanied by tumor progression, despite the standard treatment regimens. Undoubtedly, this group of patients needs to develop new methodological approaches to antitumor treatment based on a deep analysis of the molecular genetic characteristics of the tumor, the hormonal background in general, and its effect on the tumor process during pregnancy. Such a personalized approach will improve the results of treatment of young patients with BC during pregnancy.

show abstract

Section: опухоли женской репродуктивной системы Tumors Of Female Repr...unclassified

Combination of pregnancy and breast cancer

Chernyshova,

Chernyakov,

Garbukov

et al. 2023

Opuholi ženskoj reproduktivnoj sistemy

View full text Add to dashboard Cite

show abstract

“…L'étude prospective REFCORBirth est en cours, à la demande des patientes de CORasso (association de patients atteints de cancers ORL) (https://www.ecancer.fr/Professionnels-de-sante/Le-registre-des-essais-cliniques/Le-registre-des-essaiscliniques/Etudes-cliniques/Etude-REFCORBirth-etude-evaluant-la-survenue-de-cancers-dela-tete-et-du-cou-pendant-la-grossesse). Le risque foetal dépend du terme de la grossesse et de la dose reçue par le foetus au cours du traitement comme consigné dans les recommandations de la Commission Internationale de Protection Radiologique (CIPR) avec des rayonnements X [1] . Une interruption médicale de grossesse nécessite un certificat médical de l'oncologue et une Réunion de Concertation Pluridisciplinaire (RCP) spécialisée, selon l'article L.2313-1 du code de la santé.…”

Section: Introductionunclassified

Mesure de la dose délivrée hors champ à l’utérus lors d’un traitement ORL par protons

Guévelou

Trompier

Villagrasa

et al. 2020

Cancer/Radiothérapie

View full text Add to dashboard Cite

Fetal Dose Estimation During Pregnancy Using Gate Monte Carlo Simulation: Application of Hodgkin’s Lymphoma Radiotherapy

Benameur

Tahiri

Mkimel

et al. 2023

Radiation Protection Dosimetry

View full text Add to dashboard Cite

The aim of this study is to estimate the fetal radiation dose for a pregnant patient treated for Hodgkin’s lymphoma. Due to the supradiaphragmatic extensions, two plans are used for this treatment, one for supra-clavicular and the other for cervical lymph nodes, with beam energies of 18 and 6 MV, respectively. We model the ELEKTA accelerator (Versa HD Ltd, Crawly, UK) and the pregnant patient using GATE code. The accelerator is modelled based on the vendor-supplied data and the pregnant patient is modeled with a voxelized pregnant woman phantom (Katja, 29 years old) at the 24th week of pregnancy. In each plan, we estimate the absorbed dose of each fetus organ by delivering a 2 Gy for one fraction and then multiplying the result by 15 fractions to get the total prescribed dose, then we calculate the mean fetal absorbed dose. The results indicate that the mean absorbed fetal dose was 26.18 mGy.

show abstract

Radiothérapie et grossesse

Cited by 3 publications

References 14 publications

Combination of pregnancy and breast cancer

Combination of pregnancy and breast cancer

Mesure de la dose délivrée hors champ à l’utérus lors d’un traitement ORL par protons

Fetal Dose Estimation During Pregnancy Using Gate Monte Carlo Simulation: Application of Hodgkin’s Lymphoma Radiotherapy

Contact Info

Product

Resources

About